Posted in | News | Nanomedicine | Nanobusiness

pSivida Signs Evaluation Agreement for Nanotechnology Related Cardiovascular Drug Delivery

Related Stories

Global drug delivery company, pSivida Limited announced that it has entered into an evaluation agreement with an undisclosed large global medical device company to evaluate cardiovascular delivery of drugs using pSivida’s drug delivery technologies.

pSivida is a global bio-nanotech company committed to the biomedical sector and the development of drug delivery products.

pSivida owns the rights to develop and commercialize a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon™, which has applications in drug delivery, wound healing, orthopedics, and tissue engineering. The most advanced BioSilicon™ product, BrachySil™ delivers a therapeutic, P32 directly to solid tumors and is presently in Phase II clinical trials for the treatment of pancreatic cancer.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    EyePoint Pharmaceuticals, Inc.. (2019, March 19). pSivida Signs Evaluation Agreement for Nanotechnology Related Cardiovascular Drug Delivery. AZoNano. Retrieved on April 16, 2024 from https://www.azonano.com/news.aspx?newsID=4366.

  • MLA

    EyePoint Pharmaceuticals, Inc.. "pSivida Signs Evaluation Agreement for Nanotechnology Related Cardiovascular Drug Delivery". AZoNano. 16 April 2024. <https://www.azonano.com/news.aspx?newsID=4366>.

  • Chicago

    EyePoint Pharmaceuticals, Inc.. "pSivida Signs Evaluation Agreement for Nanotechnology Related Cardiovascular Drug Delivery". AZoNano. https://www.azonano.com/news.aspx?newsID=4366. (accessed April 16, 2024).

  • Harvard

    EyePoint Pharmaceuticals, Inc.. 2019. pSivida Signs Evaluation Agreement for Nanotechnology Related Cardiovascular Drug Delivery. AZoNano, viewed 16 April 2024, https://www.azonano.com/news.aspx?newsID=4366.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
(Logout)
Your comment type
Submit

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback